[go: up one dir, main page]

CO2019000942A2 - Composición y uso de un péptido - Google Patents

Composición y uso de un péptido

Info

Publication number
CO2019000942A2
CO2019000942A2 CONC2019/0000942A CO2019000942A CO2019000942A2 CO 2019000942 A2 CO2019000942 A2 CO 2019000942A2 CO 2019000942 A CO2019000942 A CO 2019000942A CO 2019000942 A2 CO2019000942 A2 CO 2019000942A2
Authority
CO
Colombia
Prior art keywords
peptide
composition
seq
treat
neglected diseases
Prior art date
Application number
CONC2019/0000942A
Other languages
English (en)
Inventor
Maria Carolina Quartim Barbosa Elias Sabbaga
Christiane Bezerra De Araujo
Original Assignee
Fund Butantan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from BR102016017666-2A external-priority patent/BR102016017666B1/pt
Application filed by Fund Butantan filed Critical Fund Butantan
Publication of CO2019000942A2 publication Critical patent/CO2019000942A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Composición que comprende un péptido según se define en SEQ ID Nº 1, 3, 4 ó 5 y un vehículo farmacéuticamente aceptable. Uso de un péptido según se define en SEQ ID Nº 1, 3, 4 ó 5 en la manufactura de una composición farmacéutica para tratar enfermedades desatendidas. Método para tratar enfermedades desatendidas.
CONC2019/0000942A 2016-07-29 2019-01-30 Composición y uso de un péptido CO2019000942A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BR102016017666-2A BR102016017666B1 (pt) 2016-07-29 Composição, e, uso de um peptídeo
PCT/BR2017/050210 WO2018018121A1 (en) 2016-07-29 2017-07-24 Composition and use of a peptide

Publications (1)

Publication Number Publication Date
CO2019000942A2 true CO2019000942A2 (es) 2019-02-08

Family

ID=59626401

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0000942A CO2019000942A2 (es) 2016-07-29 2019-01-30 Composición y uso de un péptido

Country Status (5)

Country Link
AR (1) AR109199A1 (es)
CL (1) CL2019000236A1 (es)
CO (1) CO2019000942A2 (es)
MX (1) MX2019001320A (es)
WO (1) WO2018018121A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111909254B (zh) * 2019-05-10 2024-08-20 国家纳米科学中心 抑制肿瘤活性的多肽及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR102014000521B1 (pt) 2014-01-09 2021-05-25 Proteimax Biotecnologia Ltda peptídeo, uso, composição farmacêutica, método in vitro de inibição ou de identificação de células em divisão

Also Published As

Publication number Publication date
CL2019000236A1 (es) 2019-06-07
AR109199A1 (es) 2018-11-07
WO2018018121A1 (en) 2018-02-01
MX2019001320A (es) 2019-09-19
BR102016017666A2 (pt) 2018-02-14

Similar Documents

Publication Publication Date Title
AR126205A2 (es) Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario
AR131056A2 (es) Composiciones para tratar un trastorno hipofosfatémico
WO2018190719A3 (en) Anti-sirp alpha antibodies
AR110684A1 (es) Composiciones que comprenden cepas bacterianas y método de tratamiento
PE20180927A1 (es) Moleculas de union a lag-3 y metodos de uso de las mismas
AR107871A1 (es) Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos
CL2015003135A1 (es) Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimorficas y métodos de uso.
MX2022002946A (es) Inhibidores de cdk y su uso como productos farmaceuticos.
MX2018013517A (es) Anticuerpos anti-il-1r3 humanizados.
CL2013002033A1 (es) Preparacion oral de desintegracion rapida que comprende granulos que comprenden un medicamento, un agente de desintegracion, un aglutinador, un agente de enmascaramiento y un agente de solubilizacion; metodo de preparacion; su uso para la profilaxis y/o tratamiento de un padecimiento bipolar.
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
MX2019004314A (es) Composición de apósito tópico para el tratamiento de tejido cutáneo dañado.
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
MX2016014826A (es) Conjugados de peptido-curcumina y formulaciones de los mismos.
AR112166A1 (es) Composiciones terapéuticas y métodos para el tratamiento de hepatitis b
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
EA201691018A1 (ru) Фармацевтическая композиция, содержащая смесь проферментов и ферментов
EA201791696A1 (ru) Композиция для лечения веноокклюзионной болезни печени
AR110404A1 (es) MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES FIBRÓTICAS UTILIZANDO EL INTERFERÓN-l
CL2017002765A1 (es) El uso de estimuladores sgc, activadores gc, solos y combinaciones con inhibidores pde5 para el tratamiento de úlceras digitales (du) concomitante con esclerosis sistémica (ssc).
EP4477265A3 (en) Methods of treating new-onset plaque type psoriasis using il-17 antagonists
MX2019005450A (es) Composiciones y metodos farmaceuticos.
AR101597A1 (es) Proteínas de fusión uti (inhibidor de tripsina urinaria)
CO2022001218A2 (es) Composición de inhibidor micromolecular de pi4kiiiα, método de preparación y uso
EP3925968A3 (en) Hsp70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell